|Chemical and physical data|
|Molar mass||271.243 g/mol|
|3D model (JSmol)|
Prinaberel (INN, USAN) (developmental code names ERB-041, WAY-202041) is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. It is used in scientific research to elucidate the role of the ERβ receptor. Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.
- Harris HA, Albert LM, Leathurby Y, et al. (October 2003). "Evaluation of an estrogen receptor-beta agonist in animal models of human disease". Endocrinology. 144 (10): 4241–9. doi:10.1210/en.2003-0550. PMID 14500559.
- Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA (May 2005). "Reflections on the discovery and significance of estrogen receptor beta". Endocrine Reviews. 26 (3): 465–78. doi:10.1210/er.2004-0027. PMID 15857973.
- Harris HA (2006). "Preclinical characterization of selective estrogen receptor beta agonists: new insights into their therapeutic potential". Ernst Schering Foundation Symposium Proceedings (1): 149–61. PMID 17824176.
- "Prinaberel - Wyeth phase change II, USA (endometriosis)". R & D Focus Drug News. 2006-06-05. Retrieved 2012-05-20.